By implementing a business-driven approach to IAM, enterprises can ensure its access-related processes are in full alignment with the business and are both risk-proof and audit-proof.
Topol says the unpublished results to which Wolfe is pointing don't pass the high bar of clinical proof--even though Celebrex may still pose a heart risk, and Pfizer may not have appropriately disclosed the results.
The proposals eschew the traditional risk-based U.S. regulatory approach and embrace the European style of precaution, which demands ex post proof of safety even where no current evidence reveals environmental or health harms.